Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?

President Trump has threatened tariffs of up to 200% on pharmaceutical imports, aiming to compel drugmakers to relocate manufacturing to the U.S. within 12-18 months, following a Section 232 investigation due by late July. Eli Lilly (LLY) CEO Dave Ricks stated such tariffs would negatively impact company and industry margins, though he expects the effect to be transient, advocating for tax incentives instead. While analysts anticipate significant margin compression and supply chain disruptions, they suggest the long-term impact on companies like Lilly may be manageable given their existing U.S. manufacturing capabilities and ongoing expansion plans, indicating a potentially challenging but temporary period for affected firms.

Analysis

The impending threat of up to 200% tariffs on pharmaceutical imports, following a Section 232 investigation due by the end of July, introduces significant policy-driven risk for Eli Lilly (LLY) and the broader pharmaceutical industry. According to CEO Dave Ricks on the Q1 2025 earnings call, such tariffs would have a "negative effect" on margins, a view echoed by analysts at Barclays and UBS who foresee cost inflation and supply chain disruptions. However, Lilly's management characterizes this potential impact as "transient" rather than long-term, citing the company's existing U.S. manufacturing base and ongoing investments to expand domestic production. A critical point of friction is the timeline; while the administration suggests a 12-18 month period for companies to reshore operations, UBS analysts estimate a more realistic timeframe of 4-5 years. This discrepancy suggests that if steep tariffs are implemented, Lilly will face a period of adjustment where it must either absorb costs, impacting profitability, or attempt to pass them on to consumers, which could face resistance.

Key Decisions for Investors

• Investors should closely monitor the formal announcement on pharmaceutical tariffs expected at the end of July, as the specific rate and scope will be a primary catalyst for Eli Lilly's share price.
• Be prepared for potential near-term margin compression and stock volatility for Eli Lilly if tariffs are imposed, as the company may be forced to absorb costs due to the unfeasibility of relocating all manufacturing within the proposed 12-18 month window.
• Long-term investors should assess whether the company's ongoing expansion of U.S. manufacturing provides a sufficient long-term moat to mitigate this policy risk, in line with management's view that any impact would be transient.
• Evaluate portfolio exposure across the pharmaceutical sector, as this tariff threat impacts any drugmaker reliant on the 80% of active pharmaceutical ingredients manufactured overseas.